Clinical trials overseen by Michael Rothman, M.D.

“XXX, Placebo, and XXX comparison in Patients with Major Depressive Disorder”

“Open-label XXX Continuation Therapy”

“Pharmacogenomics Blood Sampling Protocol”

“A double-blind, placebo-controlled, 3-arm fixed dose study of XXX continuous treatment for Premenstrual Dysphoric Disorder”

“A 3-Month, Double-Blind, Placebo-Controlled, Fixed Dose, Extension Study of XXX and Continuous Treatment for PMDD Patients Completing Studies XXX”

A Thirty Day Open-Label Multicenter Observational Study Assessing the Safety of xxxx Sustained Release (10 mg or 30 mg) Tablets Administered Every Twelve Hours (q12 hours) in Patients Experiencing Chronic Pain

A Three Month, Open-Label, Multicenter, Compassionate-Use Study Assessing the Safety of xxxx Sustained Release (10 mg or 30 mg) Tablets Administered Every Twelve Hours (q12 hours) in Patients Experiencing Chronic Pain

A Forty-Eight Week Study to Compare the Efficacy and Safety of xxxx (xxxx) with Placebo in Outpatients with Alzheimer’s Disease

A Twenty-Four Week Study to Compare the Efficacy and Safety of xxxx (xxxx) with Placebo in Outpatients with Vascular Dementia

A Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of xxxx Following Four-Week, Step-Wise Dose Escalations in Patients with Probable Alzheimer’s Disease

An Open-Label, Multicenter, Extended Evaluation of the Safety and Efficacy of xxxx In Patients with Alzheimer’s Disease

An Open-Label, Six-Month Extension of xxxx Studies xxxx and xxxx to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of 1 Through 6 mg B.I.D. (2-12 mg/day) xxxx in Outpatients with Probable Alzheimer’s Disease

An Open-Label, Six-Month Extension of xxxx Studies xxxx (U.S. Centers Only), xxxx and xxxx to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of 1 through 6 mg B.I.D. (2/12 mg/day) xxxx in Outpatients with probable Alzheimer’s Disease

A Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy and Safety of Three Fixed-Doses of xxxx, 3 mg, 6 mg, and 9 mg per day in Patients with Probable Mild to Moderate Alzheimer’s Disease
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety, Tolerance, and Efficacy Study of 5 and 10 mg of xxxx and 5 mg of xxxx (xxxx) in Elderly Outpatients with Insomnia with an Open-Label Extension Phase for a Maximum Duration of Twelve Months

A Multicenter, Double-Blind, Placebo-Controlled Study of the Cardiovascular Safety and Tolerability of xxxx in Otherwise Healthy Migraineurs

A 15 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of xxxx in Patients with Alzheimer’s Disease

A 30 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of xxxx in Patients with Alzheimer’s Disease

xxxx Versus xxxx and xxxx in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Single-Dose, Dose-Range-Finding Study to Assess the Efficacy and Tolerability of xxxx in the Acute Treatment of Migraine

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Range-Finding Study to Assess the Efficacy, Tolerability and Safety of xxxx (Administered As A Single Dose of 0.5 MG, 2.5 MG, or 5.0 MG) In the Treatment of Acute Migraine

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Escalating the Dose of Oral xxxx in Subjects with Acute Migraine

A Multicenter, Randomized, Open-Label, Comparative, Study of the Safety, Toleration and Efficacy of Oral xxxx for Long Term Treatment of Subjects with Acute Migraine

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of xxxx in Patients with Alzheimer’s Disease

Randomized, Double-Blind, Double-Dummy, Active-Controlled Multi-Site Crossover Investigation Comparing the Efficacy of xxxx xx (xxxx xx10 mg OR 30 mg Tablets) Administered Every Twelve Hours to xxxx xx (xxxx 5 mg Tablets) Administered Every Six Hours in Patients with Chronic Pain

Double-Blind, Randomized, Placebo-Controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of xxxx (xxxx) in Patients with Alzheimer’s Disease

A Double-Blind, Placebo-Controlled, Randomized, Dose Titration Study to Evaluate the Safety and Efficacy of xxxx
An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of xxxx in the Treatment of Elderly Outpatients with DSM-IV Major Depression

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of xxxx(xxx xx xx) in the Treatment of Moderate to Severe Vasomotor Symptoms and Atrophic Conditions Associated with the Menopause

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of xxxx xxxx (xxxxx) in Patients with Dementia Associated with Cerebrovascular Disease

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of xxxx-xx in Patients with Mild to Moderate Alzheimer’s Disease

xxxx (xxxx) Experience with Safety and Tolerability (xxxx) with Outpatients With DSM IV Psychosis

A Twelve Month, Double-Blind, Placebo-Controlled, Investigation of the Safety And Efficacy of xxxx Transdermal System (1.0mg/cm² x 20 cm²) in Patients with Dementia of the Alzheimer’s Type (Twenty-Four Month Open-Label Extension)

A Twelve Month, Double-Blind, Placebo-Controlled, Investigation of the Safety and Efficacy of xxxx Transdermal System (1.0mg/cm² x 20 cm²) in Patients with Dementia of the Alzheimer’s Type


A Double-Blind, Placebo-Controlled, Parallel-Group Assessment of the Safety and Efficacy of Two Doses of the xxxx Transdermal System (10 mg and 20 mg) in Patients with Major Depression.

A Two-Week, Double-Blind, Placebo-Controlled Trial of the Effects of xxxx 20, 50, and 100 mg BID on Cognitive Tests in Depressed Geriatric Patients.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate xxxx in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity.

Multicenter, Randomized, Double-Blind, xxxx Controlled Study of the Efficacy and Safety of xxxx in Subjects with Major Depressive Disorder Who are at Least 65 Years of Age.

A Randomized, Double-Blind, Active-and-Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Safety and Protective Effect on the Endometrium of 4 Dosage Combinations of xxxx plus xxxx.
A Multicenter, Randomized, Double-Blind, Parallel-Group Study comparing Two 12-Hour xxxx Formulations for the Treatment of Patients with Moderate to Severe Chronic Pain.

An Open-Label Study to Assess the Safety of the xxxx Transdermal System in Patients with Major Depression.

A Multicenter, Randomized, Double-Dummy, Parallel Groups Study of xxxx (xxxx oral extended release capsules) in Patients with Chronic, Moderate to Severe Pain.

A Multicenter, Non-Randomized, Open-Extension Study of xxxx (xxxx oral extended release capsules in Patients with Chronic, Moderate to Severe Pain Who Have Completed a Prior xxxx Clinical Trial.

A Double-Blind, Placebo and xxxx-Controlled, Multicenter Study Evaluating the Efficacy and Safety of xxxx in Patients with Major Depressive Disorder.

An Open Multicenter Trial of XXX in the Treatment of Patients with Mood Disorder

Double-Blind Parallel Comparison of XXX and XXX in Depressed Geriatric Outpatients

A Randomized Double-Blind, Placebo Controlled, Crossover Protocol to Evaluate the Safety and Efficacy of XXX in the Acute Treatment of Multiple Migraine Attacks

A Controlled Study of XXX in the Treatment of Alzheimer-Type Dementia

The Efficacy of Extended-Release Oral XXX in Alzheimer's Disease and Senile Dementia of the Alzheimer Type

The Safety and Efficacy of Long-Term Administration of Extended-Release Oral XXX in Alzheimer's Disease and Senile Dementia of the Alzheimer Type

Multi-Center, 36-Week, Double-Blind, Parallel Group Safety, Tolerance and Efficacy Comparison of Placebo and XXX in Outpatients with Alzheimer's disease (NINCDS/ADRDA Criteria)

Phase II, Randomized, Double-Blind, Placebo-Controlled, 12-Week Exploratory Study of XXX in Alzheimer's Disease XXX vs. Placebo in Mild to Moderate Alzheimer's Disease

Open Label Extension of XXX vs Placebo in Mild to Moderate Alzheimer's Disease

A 30-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXin patients with Alzheimer's Disease

An Open-Label, Multicenter, Extended Evaluation of the Safety and Efficacy of XXX in Patients with Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Tolerability of XXX in Patients Suffering from Dementia of the Probable Alzheimer's Type

An Open-Label Administration of XXX in Patients Suffering from Probable Dementia of the Alzheimer's Type

A Prospective, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy and Safety of XXX and XXX in Patients with Probable Mild to Moderate Alzheimer's Disease

An Open-Label, Six-Month Extension of XXX Studies XXX and XXX to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of *multiple doses of XXX* in Outpatients with Probable Alzheimer's Disease

An Open-Label, Sequential Cohort Study of XXX Designed to Prospectively Evaluate the Tolerability and Safety of Titration Doses at Weekly Increases of XXX and XXX to a Maximal Dose of XXX of XXX in Patients with Probable Alzheimer's Disease

A 16-Week, Open-Label, Safety Study of XXX with Monitoring of Serum Alanine Aminotransferase (ALT) at Weeks 4, 6, 8, 12 and 16

Double-Blind Comparative Study of the Efficacy and Safety of Orally Administered XXX and XXX in the Treatment of Patients with Community-Acquired Pneumonia

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety, Tolerance, and Efficacy Study of *two doses of XXX* and *one dose of XXX* in Elderly Outpatients with Insomnia, with an Open-Label Extension Phase for a Maximum Duration of Twelve Months

A randomized, double-blind, placebo-controlled, four-arm dose-finding study investigating the efficacy and safety of xxx doses of xxx in patients with Alzheimer’s Disease

A 48 week double-blind, placebo-controlled, parallel group, fixed dose study of the efficacy, safety and cost-effectiveness of xxx xxx in patients suffering from dementia of the probable Alzheimer’s type.

Safety and efficacy of the xxx xxx xxx system (xxx) in patients with mild to moderate Alzheimer’s Disease

A twelve month, double-blind, placebo-controlled, investigation of the safety and efficacy of xxx transdermal system (xxx) in patients with dementia of the Alzheimer’s type

A multicenter, double-blind, randomized, placebo controlled, parallel group study of the efficacy and safety of escalating the dose of oral xxx in subjects with acute Migraine
A multicenter, double-blind, randomized comparison of xxx (xxx) and xxx in the acute treatment of multiple Migraine headaches

An open, multicenter study to evaluate the tolerability and safety of xxx tablets in elderly subjects with psychotic disorders xxx versus xxx and xxx in Major Depression: Comparison of discontinuation-emergent signs and symptoms

A forty-eight week study to compare the efficacy and safety of xxx (xxx) with placebo in outpatients with Alzheimer’s Disease

A twenty-four week study to compare the efficacy and safety of xxx (xxx) with placebo in outpatients with Vascular Dementia

A double-blind, placebo controlled, parallel group study to assess the safety, tolerability and pharmacokinetics following repeated-dose up titration of xxx in patients with mild to moderate dementia of the Alzheimer’s type

An open extension study of the long term safety and efficacy of xxx (xxx or xxx) in patients suffering from dementia of the probable Alzheimer’s type.

A multicenter, randomized, open label, comparative study of the safety, toleration, and efficacy of oral xxx for long term treatment of subjects with acute migraine.

An eight-week, multicenter, parallel-group, double-blind, placebo-controlled study of xxx in elderly outpatients with DSM-IV major depression.

A 24 week, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of xxx xxx (xxx) in patients with dementia associated with cerebrovascular disease.

A randomized, double-blind, double-dummy, active-placebo controlled, parallel group evaluation of oral xxx (xxx) compared to oral xxx xxx (xxx) on migraine-related quality of life.

An open-label extension study to evaluate the long-term safety and tolerability of xxx in patients with mild to moderate Alzheimer’s Disease.

The safety and efficacy of xxx for the prevention of Alzheimer’s Disease in patients at risk.

A 30-week, open-label evaluation of xxx xxx (xxx) in patients with dementia associated with cerebrovascular disease.

A multicenter, randomized, double-blind, placebo-controlled study to evaluate xxx in patients with probable Alzheimer’s Disease of mild to moderate severity.
Sustained Efficacy Study of XXX in Patients With Panic Disorder With or Without Agoraphobia

XXX, placebo, and YYY comparison in patients with Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Flexible Doses Of XXX In The Treatment Of Hospitalized Patients With Acute Mania

A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of XXX In The Maintenance Treatment Of Patients With Bipolar Disorder

An Open-Label Study of the Safety, Tolerability, and Efficacy of Up to X mg XXX Extended Release in Patients with Generalized Anxiety Disorder

A Double-Blind, Placebo-Controlled Comparative Efficacy Study Of XXX And YYY In Producing Remission In Outpatients With Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Three Fixed Doses Of XXX In The Treatment Of Patients With Acute Schizophrenia

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of X mg and Y mg XXX Extended Release Compared to Placebo in Patients with Generalized Anxiety Disorder

An Open-Label Study to Assess The Safety of the XXX Transdermal System In Patients With Major Depression.

A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate XXX in Patients with Probable Alzheimer’s Disease of Mild to moderate Severity (90 day treatment period plus 60 day follow up)

Randomized, double-blind, placebo-controlled multicenter trial to demonstrate the clinical efficacy and safety of two different doses of XXX in patients suffering from Dementia of the Alzheimer’s Type according to DSM-IV and NINCDS/ADRDA criteria.

A Double-Blind, Placebo-Controlled Safety and Tolerability Study of XXX in Patients with Dementia of the Alzheimer’s Type.

A Double-Blind, Placebo-Controlled Study of XXX in Alzheimer Patients with Mild to Moderately Severe Cognitive Decline.

A Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety and Efficacy of Three Different Doses of XXX in Patients with Probable Alzheimer’s Disease.

A Placebo-Controlled, Randomized, Double-Blind, Multicenter Study of Efficacy and Safety of XXX in Patients with Probable Alzheimer’s Disease of Moderate Severity.
Long-Term Treatment for Patients with Primary Degenerative Dementia or Probable Alzheimer’s Disease.

The Safety and Efficacy of Long-Term Administration of Extended Release Oral XXX in Patients with Alzheimer’s Disease and Senile Dementia of the Alzheimer’s Type.


A 30 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in Patients with Alzheimer’s Disease.


A Randomized, Double-Blind, Placebo-Controlled, 12-Week Exploratory Study of the Efficacy and Safety of XXX in Alzheimer’s Disease.

An Open-Label, Multicenter, Extension Study of Safety and Efficacy of XXX Administered for 26-Weeks to Subjects with Alzheimer’s Disease.

A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of XXX in Patients with Probable Alzheimer’s Disease.

A Multicenter, Open-Label Study of the Safety and Tolerability of XXX in Patients with Alzheimer’s Disease.

Safety of XXX in the Long-Term Treatment of Alzheimer’s Disease.

A Multicenter, Double-Blind, Placebo-Controlled Study of the Cardiovascular Safety and Tolerability of XXX in Otherwise Healthy Migraineurs.

A Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Comparison of the Efficacy and Safety of three Fixed Doses of XXX in Patients with Mild to Moderate Alzheimer’s Disease.

An Open-Label, 6-Month Extension of Studies X and Y to Prospectively Evaluate the Long-Term Safety, Tolerability and Efficacy of XXX in Outpatients with Probable Alzheimer’s Disease.
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability and Pharmacokinetics Following Repeated Dose Titration of XXX in Patients with Mild to Moderate Dementia of the Alzheimer’s Type.

An Open-Label, Administration Study of XXX in Patients Suffering Dementia of the Probable Alzheimer’s Type.


A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of a Fixed Dose XXX tablet in Patients with Probable Alzheimer’s Disease.


A Multicenter, Double-Blind, Randomized, Parallel Group Single Dose Placebo-Controlled Study to Evaluate the Safety and Effectiveness of XXX in Alleviating the Headache Pain of an Acute Migraine.

The Efficacy and Safety of XXX Vs. YYY in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Trial.

A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of XXX in Patients with Probable Alzheimer’s Disease with Long-Term Open-Label Extension.

An Open-Label Sequential Cohort Study of XXX Designed to Prospectively Evaluate the Tolerability and Safety of Titrating Doses at Weekly Increases to a Maximal Dose of XXX in Patients with Probable Alzheimer’s Disease.

A Twelve-Month, Double-Blind, Placebo-Controlled Investigation of the safety and Efficacy of XXX in Patients with Senile Dementia of the Alzheimer’s Type.

A Multicenter, Long-Term Study to Maximize Migraine Relief with XXX.

XXX Versus YYY and ZZZ in Major Depression: Comparison of Discontinuation - Emergent Signs and Symptoms.

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multi-Site Crossover Investigation Comparing the Efficacy of XXX SR Administered Every Twelve Hours or XXX IR Administered Every Six Hours in Patients with Chronic Pain.

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multi-Site Crossover Investigation Comparing the Efficacy of XXX Administered Every 12 Hours to YYY Administered Every 6 Hours in Patients with Chronic Pain.
A Three Month, Open-Label Multicenter, Compassionate-Use Study Assessing the Safety of XXX SR SR Tablets Administered Every Twelve Hours (q 12 hours) in Patients Experiencing Chronic Pain.

A Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of XXX in Patients with Probable Alzheimer’s Disease.

A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of a Fixed Dose XXX Comparing a Loading Dose Phase and No Loading Dose Phase Versus Placebo in Patients with Probable Alzheimer’s Disease.

Long-Term Treatment with XXX for Patients with Probable Alzheimer’s Disease.

Open Evaluation of the Long-Term Efficacy, Safety and Tolerability of XXX in the Acute Treatment of Migraine Attacks.

A Randomized, Double-Blind, Placebo-Controlled 4-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of XXX in Patients with Alzheimer’s Disease.

A Double-Blind, Randomized, Placebo-Controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of XXX in Patients with Alzheimer’s Disease.

A Twelve-Month Study of XXX in the Acute Treatment of Migraine.

A Twelve-Month, Double-Blind, Placebo-Controlled Investigation of the Safety and Efficacy of XXX in Patients with Senile Dementia of the Alzheimer’s Type. Twenty-Four Month, Open-Label Extension.

Strategies for Switching from Conventional Anti-Psychotic Drugs to XXX.

A Double-Blind, XXX-Controlled, Safety and Dose Finding Study in the Treatment of Schizophrenia.

A Placebo-Controlled Study of the Efficacy of XXX Administered to Schizophrenic Patients for 42 Days.

An Open-Label Assessment of the Long-Term Safety of XXX.

An Eight-Week, Multi-Center, Parallel-Group, Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Elderly Outpatients with DSM-IV Major Depression.

A Phase III Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Psychosis, with YYY as Active Control.
An Open-Label Follow-On Study of the Long-Term Safety of XXX in Patients with Psychosis.

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of XXX in Patients with Mild to Moderate Alzheimer’s Disease.


A Double-Blind, 12-Month Safety and Efficacy Trial of XXX in Patients with Probable Alzheimer’s Disease

A Double-Blind, 12-Month Safety and Efficacy Study of XXX Added to Treatment with YYY in Patients with Probable Alzheimer’s Disease.

A Multi-Center Placebo-Controlled, Double-Blind Study Comparing the Safety and Efficacy of XXX and YYY in Subjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care. (Protocol A)

A Double-Blind, Six-Month Continuation Protocol for Subjects who Successfully Completed Protocol A.

A 52-Week (1 Year), Open Extension Study Evaluating the Safety and Efficacy of Continued Administration of XXX in the Treatment of Subjects who have participated in Previous Trials.

The Comparative Efficacy of XXX, YYY, and ZZZ for Cognition in Schizophrenia.

A Two-Week, Double-Blind, Placebo-Controlled Trial of the Effects of XXX on Cognitive Tests in Depressed Geriatric Patients.

A Double-Blind, Placebo-Controlled, Parallel-Group Assessment of the Safety and Efficacy of Two Doses of the XXX Transdermal System in Patients with Major Depression.

Single dose, Double-Blind, Safety And Efficacy Study Of XXX, YYY And ZZZ In Subjects With Acute Migraine Attacks

A Multicenter, Open Label Extension Study To Evaluate The Long-Term Safety and Effectiveness of XXX in Patients with Chronic Pain

Delay in Nursing Home Placement of Alzheimer’s Disease (AD) Patients Treated in the XXX Clinical Program

Cost-Effectiveness and Functional Outcomes of XXX in the Treatment of Schizophrenia in Usual Clinical Practice: A Randomized Clinical Study
A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of XXX in Patients with Mild to Moderate Probable Alzheimer’s Disease.

A 6-Month Study of XXX in the Acute Treatment of Migraine.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate XXX in Patients with Possible or Probable Alzheimer’s Disease of Mild to Moderate Severity.

XXX Versus Placebo in Mild to Moderate Alzheimer’s Disease.

The Efficacy of Extended Oral XXX in Alzheimer’s Disease and Senile Dementia of the Alzheimer’s Type.

Open Label Extension of XXX vs. Placebo in Mild to Moderate Alzheimer’s Disease.

A Study Evaluating the Safety and Efficacy of XXX for the Treatment of Migraine Headache Pain.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate XXX in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity.

A Multicenter, Open Label Extension Study To Evaluate The Long-Term Safety and Effectiveness of XXXX CR in Patients with Chronic Pain

A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Groups Study of XXXX (XXXX XXXX oral extended release capsules) in Patients with Chronic, Moderate to Severe Pain

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Doses of XXXX (XXXX) Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headaches

A Prospective, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy and Safety of Three Fixed-Doses of xxx, Per Day in Patients with Probable Mild to Moderate Alzheimer’s Disease.

An Open-Label, Six-Month Extension of xxxx Studies xxx and xxx to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of xxxxxx in Outpatients With Probable Alzheimer’s Disease.

A Multicenter, Double-Blind, Placebo-Controlled Study of the Cardiovascular Safety and Tolerability of’ xxx in Otherwise Healthy Migraineurs.

The efficacy and safety of two doses of xxx Vs xxx in the acute treatment of migraine: A Randomized, double-blind, placebo-controlled, single-dose trial.
A 16-week randomized, double-blind, placebo-controlled, parallel-group, dose-response, multicenter, study of xxx once-a-day formulation with a 16-month open-label extension in patients with dementia of the Alzheimer’s type.

A multicenter, double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of oral xxx in subjects with acute migraine

A Multicenter, Randomized, Open Label, Comparative Study of the Safety, Toleration and Efficacy of Oral xxxx For Long Term Treatment of Subjects with Acute Migraine.

Safety and Efficacy of the xxxx Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease.

Open-label extension of xxx registration phase efficacy trials using xxx transdermal therapeutic system (tts) in Patients with Alzheimer’s Disease.

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of xxx in Patients with Alzheimer’s Disease.

Open Evaluation of the Long-Term efficacy, safety and tolerability of 1.4 mg SC xxx in the acute treatment of migraine attacks

A 12-month Study of xxx in the Acute Treatment of Migraine

An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of xxx in Elderly Outpatients with DSM-IV Major Depression

Double-blind, xxx-controlled, safety and dose-finding study in the treatment of Schizophrenia.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate xxx in Patients with Possible or Probable Alzheimer’s Disease of Mild to Moderate Severity

A Randomized, Double-Blind, Placebo-Controlled Study To Determine The Safety And Efficacy of xxx In Patients With Mild To Moderate Probable Alzheimer’s Disease

A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate xxx in Patients with Probable Alzheimer’s Disease of Mild to moderate Severity (90 day treatment period plus 60 day follow up)

A Single Dose, Double-Blind, Safety and Efficacy Study of xxx, xxx and xxx in Subjects with Acute Migraine Attacks

An Open-Label, Repeat Dose, Long-Term Safety of xxx in Subjects with...
Acute Migraine Attacks

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Safety and Tolerability, of xx mg xxx Extended Release Compared to Placebo in Patients with Generalized Anxiety Disorder

An Open-Label Study of the Safety, Tolerability, and Efficacy of up to xx mg xxx Extended Release in Patients with Generalized Anxiety Disorder

XXX for the Study of Obsessive-Compulsive Disorder XXX

XXX for the Study of Hypnotic Agent XXX

XXX for the Study of Antidepressant Drug, XXX

XXX for the Study of T Cell Function in Depression

XXX Corporate grant for the Study of Seasonal Affective Disorder

A Double-Blind Parallel Comparison of XXX, XXX and Placebo in Inpatients with major Depression or Bipolar Disorder

Efficacy and Safety of XXX in Patients with Alzheimer’s Disease

An Open Multicenter Trial of XXX and Placebo in the Treatment of Depressed Inpatients

Short and Long Term Discontinuation of XXX in the Treatment of Panic Disorder with Agoraphobia

A Pilot Observation to Develop Information on Sexual Functioning and Quality of Life in Patients with Obsessive Compulsive Disorder

A Controlled Study of XXX in the Treatment of Alzheimer-Type Dementia

A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in Schizophrenic Patients

An Open-Label Assessment of the Long-Term Safety of XXX in the Treatment of Schizophrenic Patients

Double-Blind Evaluation of the Clinical Usefulness of Low Dose XXX for the Symptomatic Treatment of Dementia in Institutionalized Patients

A Double-Blind Study of XXX in the Treatment of Panic Disorder
A Double-Blind Study of XXX in Generalized Anxiety Disorder

A Double-Blind Study of XXX and XXX in Highly Anxious Outpatients with Major Depression

An Open-Label Study of XXX in Generalized Anxiety Disorder

A Double-Blind Comparison of XXX and XXX in the Prevention of Psychotic Relapse in Outpatients with Schizophrenia

A Double-Blind Study of Single Doses of XXX in Alzheimer’s Disease

Clinical Evaluation of Extended-Release Oral XXX in the Treatment of Patients with Dementia of the Alzheimer’s Type

An Open-Label Extension of Extended-Release Oral XXX Treatment of Patients with Dementia of the Alzheimer’s Type

A Double-Blind Placebo-Controlled Dose Escalation Study of the Safety and Efficacy of Oral XXX in the Treatment of Patients with Panic Disorder

A Double-Blind, XXX-Referenced Study of the Safety and Efficacy of Two Doses of XXX in Schizophrenic Patients

A Phase II, Double-Blind Study of 3 Different Doses of XXX vs. Placebo in Outpatients Suffering from Depression

A Double-Blind Study Evaluating the Safety and Efficacy of Two Dose Regimens of Oral XXX and XXX in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder

A Phase III, Double-Blind, Comparative and Placebo-Controlled Parallel-Group Safety, Tolerance, and Efficacy Study of XXX, Compared with XXX or Placebo in Adult Outpatients with Insomnia

XXX Dose Titration Study

A Double-Blind, Placebo-Controlled Dose-Escalation Study of the Safety and Efficacy of Oral XXX in the Treatment of Patients with Panic Disorder

Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Three Doses of XXX Administered for 12 Weeks to Subjects with Alzheimer’s Disease

Phase II Open-Label, Multicenter Extension Study of the Safety and Efficacy of XXX Administered for Twenty-Six Weeks to Subjects with Alzheimer’s Disease
A Phase II, Eight Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral XXX in Outpatients with Major Depressive Disorder

A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled, Parallel-Group Study Comparison of the Efficacy and Safety of Three Fixed-Doses of XXX per Day in Patients with Probable Mild to Moderate Alzheimer’s Disease

A Prospective, Randomized, Multi-Center, Double-Blind, Parallel-Group Study of the Efficacy and Safety of XXX as Compared to XXX and Placebo in Institutionalized Patients with Chronic Schizophrenia

Six Month Efficacy and Safety of XXX in Patients with Alzheimer’s Disease

Open-Label Extension of Protocol XXX: XXX Tartrate vs. Placebo in Mild to Moderate Alzheimer’s Disease

Preliminary Double-Blind, Placebo-Controlled Evaluation of XXX Capsules in Outpatients with Alzheimer’s Disease

A Placebo-Controlled, Randomized, Double-Blind, Multicenter Study of the Efficacy and Safety of XXX in Patients with Probable Alzheimer’s Disease of Moderate Severity

Six Month, Open-Label Evaluation of the Safety and Efficacy of XXX Followed by a Randomized, Double-Blind, Placebo-Controlled One Year Evaluation of XXX in Prophylactic Treatment of Recurrent Major Depression

A Double-Blind, Placebo-Controlled, Parallel, Dose-Ranging Assessment of the Safety and Tolerability of the XXX Transdermal System in Patients with Major Depression (Unipolar)

Forty-Eight Week Efficacy and Safety Study of XXX in Patients with Alzheimer’s Disease

Twenty-Four Week Efficacy and Safety Study of XXX in Patients with Vascular Dementia

A Fifty-Two Week, Double-Blind Extension Study Evaluating the Safety and Efficacy of Two Dose Regimens of XXX and XXX in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder Who Have Successfully Completed Protocol XXX

Safety and Efficacy of XXX Compared to Placebo in the Treatment of Schizophrenia

An Open-Label, Six-Month Extension of XXX Studies XXX and XXX to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of 1 through 6 mg BID XXX in Outpatients with Probable Alzheimer’s Disease
A Multicenter, Open-Label Trial Evaluating the Safety and Tolerability of XXX in the Treatment of Elderly Subjects with Selected Idiopathic and Organic Psychoses

A Prospective, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Groups Comparison of the Efficacy and Safety of XXX and XXX in Patients with Mild to Moderate Probable Alzheimer’s Disease

A Multicenter, Placebo-Controlled Study of Relapse-Prevention by Long-Term Treatment with High or Low Doses of XXX in Out-Patients with Recurrent Major Depressive Episode

Open Label Extension of Study XXX to Evaluate Long-Term Administration of XXX in the Treatment of Patients with Dementia of the Alzheimer’s Type

Forty-Eight Week Efficacy and Safety Study of XXX in Patients with Alzheimer’s Disease

An Open-Label Sequential Cohort Study of XXX Designed to Prospectively Evaluate the Tolerability and Safety of Titration Doses at Weekly Increases of XXX and XXX to a Maximal Daily dose of XXX of XXX in Outpatients with Probable Alzheimer’s Disease

A Forty-Eight Week Study to Compare the Efficacy and Safety of XXX with Placebo in Outpatients with Alzheimer’s Disease

A Twenty-Four Week Study to Compare the Efficacy and Safety of XXX with Placebo in Outpatients with Alzheimer’s Disease

A Twelve Month, Double-Blind, Placebo-Controlled, Investigation of the Safety and Efficacy of XXX Transdermal System

A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of XXX in Patients with Probable Alzheimer’s Disease with Long-Term Open-Label Extension

A 24-Week, Double-Blind, Placebo Controlled, Parallel Group, Fixed Dose Study of the Efficacy and Tolerability of XXX in Patients Suffering from Dementia of the Probable Alzheimer’s Type

A Double-Blind, Randomized, Comparison of the Safety and Efficacy of XXX and XXX in Treatment Resistant Schizophrenic Patients

XXX Plus XXX Versus XXX Plus XXX in the Treatment of Major Depression

A Phase III, Multicenter, Open Label Study Evaluating the Toleration and Safety of 3 Days Treatment with Intramuscular XXX or XXX Followed by 4 Days of Treatment with Oral XXX or XXX in Subjects with a Diagnosis of Psychotic Disorder
A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study of XXX in Schizophrenic and Schizoaffective Patients

Safety and Efficacy of the XXX Transdermal Therapeutic System in Patients with Mild to Moderate Alzheimer’s Disease

Double-Blind Evaluation of XXX vs XXX on the Long-Term Morbidity of Early Psychotic Patients

A Phase II Multicenter, Double-Blind, Parallel, Randomized Comparison of Oral XXX and Placebo Over 28 Days in Patients with Schizophrenia

A Double-Blind, Placebo Controlled Trial to Compare the Clinical Effects of Immediate Release XXX and Modified Release XXX in the Treatment of Major Depression in Elderly Patients

Efficacy, Tolerability, and Safety of XXX in the Treatment of Alzheimer’s Disease

An Open-Label Study to Evaluate the Safety and Efficacy of XXX through XXX or XXX in Patients with Mild to Severe Probable Alzheimer’s Disease in the Community Setting

Open Evaluation of the Long Term Efficacy, Safety and Tolerability of XXX in the Acute Treatment of Migraine Attacks

A Double-Blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release XXX in the Treatment of Panic Disorder

Double-Blind, Placebo-Controlled Study of XXX and XXX in Inpatients with Major Depression and Melancholia

XXX Versus XXX and XXX in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms

A Long-Term, Open Label, Phase III Trial to Evaluate the Efficacy, Safety and Tolerability of XXX in the Acute Treatment of Migraine Attacks in Subjects Who Previously Completed the XXX or XXX Trial and in XXX Naive Subjects

A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study of XXX in Schizophrenic and Schizoaffective Patients

A Multicenter, Open-Label, Long-Term Follow-up, Safety Study of XXX in Schizophrenia and Schizoaffective Patients who Participated in XXX

An Open Extension Study of the Long Term Safety and Efficacy of XXX in Patients Suffering from Dementia of the Probable Alzheimer’s Type
The Efficacy, Safety and Tolerability of XXX Versus Placebo for One Year in Patients Diagnosed with Alzheimer’s Disease

An Open-Label, Long-Term, Safety Study of Transdermal XXX in the Treatment of Anxious Outpatients

A Multicenter, Double-Blind, Randomized Comparison of XXX and XXX in the Acute Treatment of Multiple Migraine Headaches

The Efficacy, Safety and Tolerability of XXX Versus Placebo, Administered for One Year in Patients with Probable Alzheimer’s Disease

An Open-Label, Long-Term, Safety Study of Transdermal XXX in the Treatment of Anxious Outpatients

A Phase III Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Psychosis, with XXX as Active Control

An Open-Lable Follow-On Study of the Long-Term Safety of XXX in Patients with Psychosis

A Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of XXX in Outpatients with Major Depression

The Efficacy, Safety, and Tolerability of XXX Versus Placebo Administered for One Year in Patients with Probable Alzheimer’s Disease

A Double-Blind, Randomized Trial of Three Fixed Doses of Transdermal XXX Compared to Placebo in the Treatment of Anxious Outpatients

A Double-Blind, Placebo-Controlled Safety and Tolerability of XXX in Patients with Dementia of the Alzheimer Type

XXX vs. XXX in the Treatment of Schizophrenia in Elderly Subjects

An Open-Lable Study to Evaluate the Safety and Efficacy of x mg b.i.d. (xg/day) Through x mg b.i.d. (x mg/day) of XXX™ in Patients with Mild to Severe probable Alzheimer’s Disease in the Community Setting

An Open-Label Extension to Evaluate the Long-Term Safety and Tolerability of XXX in Patients with Mild to Moderate Alzheimer’s Disease

A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of XXX and XXX for the Treatment of Migraine Headache Pain
Weekly Enteric-Coated XXX vs Daily XXX or Placebo in the Continuation Treatment of Major Depressive Disorder

A 30 Week, Open-Label Evaluation of XXX in Patients with Dementia Associated with Cerebrovascular Disease

A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of XXX for the Treatment of Migraine Headache Pain

XXX in the Management of Behavioral Disturbances and/or Psychosis in Demented Nursing Home Patients

XXX Compare with Placebo and XXX in Outpatients with Generalized Anxiety Disorder

A Multicenter, Placebo and Active Control, Double-Blind Randomized Study of the Efficacy, Safety and Pharmacokinetics of XXX in Schizophrenic and Schizoaffective Patients

Long-Term, Efficacy, Safety, and Health Care Outcomes in Patients Receiving Open-Label XXX Therapy

A Multicenter, Placebo Control, Double-Blind Randomized Study of the Efficacy, Safety, and Pharmacokinetics of XXX in Schizophrenic and Schizoaffective Patients


XXX Compared with Placebo and XXX in Outpatients with Generalized Anxiety Disorder

Long-Term, Efficacy, Safety, and Health Care Outcomes in Patients Receiving Open-Label XXX Therapy

Long-term Safety of XXX in the Treatment of Alzheimer’s Disease

A 52-Week (1 Year), Open-Extension Study Evaluating the Safety and Efficacy of Continued Administration of XXX Daily of XXX in the Treatment of Subjects Who Have Participated in Previous XXX Clinical Trials

A Double-Blind, Placebo and XXX-Controlled, Multicenter Study Evaluating the Safety and Efficacy of XXX in Schizophrenic Patients

A Double-Blind, Placebo and XXX-Controlled, Multicenter Study Evaluating the Safety and Efficacy of XXX in Schizophrenic Patients

Efficacy and Long-Term Tolerability of XXX in Patients with Moderately Severe to Severe Alzheimer’s Disease
A Six-Week, Double-Blind, Placebo and XXX-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral XXX in Outpatients with Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate XXX in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity

A Placebo-Controlled Study of XXX and XXX in Patients with Generalized Anxiety Disorder

A Multi-Center, Placebo-Controlled, Double-Blind Study Comparing the Safety and Efficacy of XXX and XXX in Subjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care

An Echocardiographic Follow-Up Study of Subjects Who Participated in The XXX Research Protocol XXX

A Phase III, Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Psychosis, with XXX as Active Control

A Phase III, Open-Label, Follow-On Study of the Long-Term Safety of XXX in Patients with Psychosis

Treatment of depression in later life. Comparison of xxxx and xxxxx in a geriatric population, Western Psychiatric Institute and Clinic

EEG sleep, aging and mental illness, National Institute of Mental Health #MH37869-02

Psychobiology of delusional depression, Western Psychiatric Institute and Clinic (submitted to NIMH)

xxxxxx in obsessive compulsive disorders, Ciba-Geigy Grant

A Placebo Comparative Study of xxxxxxx in Depressed Inpatients Undergoing ECT

xxxxx in Depressed Outpatients

A Randomized Comparative Study of xxxxxxx and The Treatment of Depression As Used in a Clinical Practice Setting

An Open Label Multi-center Clinical Trial Evaluating the Safety and Efficacy of xxxxx xxxx in Patients with Alzheimer’s Disease

Double-blind, Placebo-controlled Study of xxxx and xxxxx in Geriatric Outpatients with Major Depression
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate xxxxx in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity

xxxxx in the Management of Behavioral Disturbances and/or Psychosis in Demented Nursing Home Patients

The Safety and Efficacy of XXX in Slowing the Progression of the Symptoms of Alzheimer's Disease.

A 12 week, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of XXX in Patients Suffering from Posttraumatic Stress Disorder (PTSD).

XXX Versus XXX and Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia

A Randomized, Double-Blind, Placebo-Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of two doses of XXX in Patients with Generalized Anxiety Disorder.

An Open Label, Six Month Extension of XXX Prospectively Evaluate the Long-Term Safety and Tolerability and Efficacy of 1 through 6 mg b.i.d. (2-12mg/day) of XXX in Outpatients with Probable Alzheimer’s Disease

An Open Label Sequential Cohort Study of XXX Designed to Prospectively Evaluate the Tolerability and Safety of Titrating Doses at Weekly Increases of 3 mg/day and 4 mg/day to a Maximal Dose of 12mg/day of XXX in Patients with Probable Alzheimer’s Disease.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate XXX in Patients with Possible or Probable Alzheimer’s Disease of Mild to Moderate Severity.

A Multicenter, Double-blind, Placebo-controlled, Randomized Trial and an Open Label, Long-Term Tolerability Trial of XXX for the Acute Treatment of Migraine Headaches in Adolescent Subjects

A Double-Blind, Randomized Trial of Three Fixed Doses of Transdermal XXX Compared to Placebo in the Treatment of Anxious Outpatients.

XXX for the Treatment of Mild Cognitive Impairment and Prevention of Conversion to Alzheimer’s Disease

Long-term Safety and Efficacy of XXX in the Treatment of Alzheimer’s Disease. Extension

Two-Period Crossover Comparison of XXX (two doses) to XXX (two doses) in the Acute Treatment of Migraine.
A Double-Blind, 12-Month Safety and Efficacy Trial of Two Doses of XXX in Patients with Probable Alzheimer’s Disease.

A Double-Blind, 12-Month Safety and Efficacy Trial of XXX Added to Treatment with XXX in Patients with Probable Alzheimer’s Disease.

A Double-Blind, Randomized Trial Comparing Four Doses of an Intramuscular Formulation of XXX And Placebo in the Treatment of Outpatients With Migraine Headache.

A Double-blind, Placebo-Controlled Safety and Tolerability Study of XXX in Patients with Dementia of the Alzheimer Type.

Long-Term, Safety and Efficacy of XXX in the Treatment of Alzheimer’s Disease.

Efficacy, Tolerability and Safety of XXX In The Treatment of Alzheimer’s Disease

A Randomized, Multicenter, Double-blind, Placebo-Controlled, Fixed-Dose, 7-Week Evaluation of the Efficacy and Safety of XXX in Patients with Major Depression.

A Study of Low-Dose XXX, in Patients with Generalized Anxiety Disorder (GAD); A Randomized, Double-Blind, Placebo-Controlled, Parrallel-Group, Multicenter Study to Assess Efficacy and Safety.

A Double Blind, Randomized, Multi-Center, Parallel Design Study to Evaluate the Efficacy and Safety of XXX in Comparison with Placebo and XXX in Outpatients with Major Depressive Disorder

An Open Label, Six Month Extension of XXX Prospectively Evaluate the Long-Term Safety and Tolerability and Efficacy of 1 through 6 mg b.i.d. (2-12mg/day) of XXX in Outpatients with Probable Alzheimer’s Disease

An Open Label Sequential Cohort Study of XXX Designed to Prospectively Evaluate the Tolerability and Safety of Titrating Doses at Weekly Increases of 3 mg/day and 4 mg/day to a Maximal Dose of 12mg/day of XXX in Patients with Probable Alzheimer’s Disease.

Compared with Placebo and XXX in Outpatients with Generalized Anxiety Disorder.

A Multicenter, Double-blind, Randomized, Fixed-Dose Evaluation of the Efficacy and Safety of XXX, XXX and Placebo in Outpatients with Unipolar Depression and Protocol Amendment 1; Incorporating Participation in Genotype Research (Optional for both Study Centers and Patients).

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of XXX in Patients with Mild to Moderate Alzheimer’s Disease.
An Open-label, Long-Term, Safety Study of Transdermal XXX in the Treatment of Anxious Outpatients

An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of XXX in Elderly Outpatients with DSM-IV Major Depression.

A Twelve Month, Double-Blind, Placebo-Controlled, Investigation of the Safety and Efficacy of XXX Transdermal System in Patients with Dementia of the Alzheimer’s Type. Twenty-Four Month Open-Label Extension

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of three Doses of XXX in Patients with Alzheimer’s Disease

A Double-Blind, Parallel, Placebo-Controlled, Single-Dose Study of the Activity of Four Dose Levels of XXX for the Treatment of Migraine Headaches With or Without an Aura in Females.

A Multicenter, Double-Blind, Randomized Comparison of XXX and XXX in the Acute Treatment of Migraine Headaches.

A Multicenter, Randomized, Open Label, Comparative Study of the Safety, Toleration, and Efficacy of XXX for Long Term Treatment of Subjects with Acute Migraine

XXX Versus XXX And XXX In Major Depression: Comparison of Discontinuation - Emergent Signs and Symptoms.

A Multicenter, Double-Blind, Randomized, Placebo Controlled Parallel Group, Study of the Efficacy and Safety of Oral XXX in Subjects with Acute Migraine

A Twelve Month, Double-Blind Placebo-Controlled, Investigation of the Safety and Efficacy of XXX Transdermal System in Patients with Dementia of the Alzheimer’s Type

A Multicenter, Double-Blind Trial to Evaluate the Efficacy and Safety of XXX Compared to Placebo in the Management of Agitated Behavior in Patients with DAT, MID or Mixed Dementia

An Open Label, Long -Term Trial Evaluating the Safety of XXX in the Treatment of Patients with Migraine Headache With or Without Aura

A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of XXX and XXX in Outpatients with Moderate to Severe Recurrent Major Depression

A Double-Blind, Placebo-Controlled, Parallel-Group Assessment of the Safety and Efficacy of Two Doses of the XXX in Patients with Major Depression

A Randomized, Double-Blind, Placebo-controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of XXX in Patients with Generalized Anxiety Disorder

A Randomized, Multicenter, Double-blind, Placebo-Controlled, Fixed-Dose, 7-Week Evaluation of the Efficacy and Safety of XXX in Patients with Major Depression.

A 12 week, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of XXX in Patients Suffering from Posttraumatic Stress Disorder (PTSD).

A Study of Low-Dose XXX, in Patients with Generalized Anxiety Disorder (GAD); A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety.

A Randomized, Double-Blind, Placebo-Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of XXX in Patients with Generalized Anxiety Disorder.

A Double Blind, Randomized, Multi-Center, Parallel Design Study to Evaluate the Efficacy and Safety of XXX in Comparison with Placebo and XXX in Outpatients with Major Depressive Disorder

Compared with Placebo and XXX in Outpatients with Generalized Anxiety Disorder

A Multicenter, Double-Blind, Randomized, Fixed-Dose Evaluation of the Efficacy and Safety of XXX, XXX and Placebo in Outpatients with Unipolar Depression and Protocol Amendment 1; Incorporating Participation in Genotype Research (Optional for both Study Centers and Patients)

A Single Dose, Double-Blind, Safety and Efficacy Study of XXX, and XXX in Subjects with Acute Migraine attacks.

A Multicenter, Double-Blind Controlled Randomized Trial and an Open Label Long Term, Tolerability Trial of XXX for the Acute Treatment of Migraine Headaches in Adolescent Subjects

The Safety and Efficacy of XXX in Slowing the Progression of the Symptoms of Alzheimer's Disease.

XXX versus XXX and Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia

A Double-Blind, Randomized Trial of Three Fixed Doses of Transdermal XXX Compared to Placebo in the Treatment of Anxious Outpatients.
XXX for the Treatment of Mild Cognitive Impairment and Prevention of Conversion to Alzheimer’s Disease

Long-term Safety and Efficacy of XXX in the Treatment of Alzheimer’s Disease. Extension

Two-Period Crossover Comparison of XXX (two doses) to XXX (two doses) in the Acute Treatment of Migraine.

A Double-Blind, 12-Month Safety and Efficacy Trial of Two Doses of XXX in Patients with Probable Alzheimer’s Disease.

A Double-Blind, 12-Month Safety and Efficacy Trial of XXX Added to Treatment with XXX in Patients with Probable Alzheimer’s Disease.

A Double-Blind, Randomized Trial Comparing Four Doses of an Intramuscular Formulation of XXX And Placebo in the Treatment of Outpatients with Migraine Headache.

A Double-blind, Placebo-Controlled Safety and Tolerability Study of XXX in Patients with Dementia of the Alzheimer Type.

Long-Term, Safety and Efficacy of XXX in the Treatment of Alzheimer’s Disease.

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of XXX in Patients with Mild to Moderate Alzheimer’s Disease.

An Open-label, Long-Term, Safety Study of Transdermal XXX in the Treatment of Anxious Outpatients

An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of XXX in Elderly Outpatients with DSM-IV Major Depression.

A Twelve Month, Double-Blind, Placebo-Controlled, Investigation of the Safety and Efficacy of XXX Transdermal System in Patients with Dementia of the Alzheimer’s Type. Twenty-Four Month Open-Label Extension

A Double-Blind, Parallel, Placebo-Controlled, Single-Dose Study of the Activity of Four Dose Levels of XXX for the Treatment of Migraine Headaches With or Without an Aura in Females.

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of three Doses of XXX in Patients with Alzheimer’s Disease.

XXX versus XXX and XXX in Major Depression: Comparison of Discontinuation - Emergent Signs and Symptoms.
A Ten Week, Multicenter, Double-Blind, Randomized Clinical Trial of Two Fixed Doses of XXX and Placebo in the treatment of Outpatients with Major Depression

A Open Label, Multicenter, Efficacy and Safety Clinical Trial of Three Fixed Doses of XXX in the Treatment of Outpatients with Major Depression

A Double-Blind Placebo Controlled Parallel Group Dosage: Determination Study of Low Doses of XXX in Depressed Patients.

An Open Label, One Year, Efficacy and Safety Clinical Trial of Three Fixed Doses of XXX in the Treatment of Outpatients with Major Depression

A Six Month, Multicenter, Double-Blind, Randomized Efficacy and Safety Trial of Three Fixed Doses of XXX and Placebo in the Treatment of Outpatients with Major Depression

Long-Term Treatment for Patients with Primary Degenerative Dementia or Probable Alzheimer's Disease

The Efficacy of Extended-Release XX in Alzheimer's Disease and Senile Dementia of the Alzheimer type

An Open Label, Multicenter, Extended Evaluation of the Safety and Efficacy of XXX in Patients with Alzheimer's Disease

Open Label Extension of XXX Vs Placebo in Mild to Moderate Alzheimer's Disease

An Open Label Administration Study of XXX in Patients Suffering from Dementia of the Probable Alzheimer's Type

Clinical Evaluation of Extended-Release XXX in the Treatment of Patients with Dementia of the Alzheimer's Type

An Open-Label, Six Month Extension of XXX Studies XXX and XXX to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy X Through X B.I.D. XXX in Outpatients With Probable Alzheimer's Disease.

A Randomized, Triple-Blind, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of XXX and XXX for the Acute Treatment of Migraine

An Open-Label, Sequential Cohort Study of XXX, Designed to Prospectively Evaluate the Tolerability and Safety of Titrating Doses at Weekly Increases of XXX to a Maximal Dose of in Patients with Probable Alzheimer's Disease.
A Twelve Month, Double-Blind, Placebo-Controlled, Investigation of the Safety and Efficacy of XXX in Patients with Dementia of the Alzheimer's Type.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Single-Dose, Dose-Range-Finding Study to Assess the Efficacy and Tolerability of XXX in the Acute Treatment of Migraine.

A Twelve Month, Double-Blind, Placebo-Controlled, Investigation of the Safety and Efficacy of XXX in Patients with Senile Dementia of the Alzheimer's Type.

A Phase Ila Two Center Placebo-Controlled Study of three Dosages XXX of XXX in Patients with Mild to Moderate Alzheimer's Disease.

A Two-Part, Placebo-Controlled, In-Clinic, Study to Explore the Preliminary Safety, Tolerability, and Efficacy of Intravenous XXX in the Acute Treatment of Migraine.

A Forty-Eight Week Study to Compare the Efficacy and Safety of XXX with Placebo in OutPatients with Alzheimer's Disease.

A Twenty-Four Week Study to Compare the Efficacy and Safety of XXX with Placebo in OutPatients with Vascular Dementia.

A 54 Week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of XXX on Functional Outcomes in Patients With Alzheimer's Disease with a Staged Crossover to Open-Label XXX Treatment.

A 24 Week, Double-Blind, Placebo Controlled, Parallel Group, Fixed Dose Study of the Efficacy and Tolerability of XXX and XXX o.d. in Patients Suffering from Dementia of the Probable Alzheimer's Type.


A Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Fixed Dose XXX Comparing a Loading Dose Phase and No Loading Dose Phase Versus Placebo in Patients with Probable Alzheimer's Disease.

A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of XXX (XX, XX or XX mg) Given Subcutaneously in the Acute Treatment of Migraine.
Efficacy, Tolerability and Safety of XXX in the Treatment of Alzheimer's Disease.

A multicentre, double-blind, placebo-controlled, randomized, parallel group study to evaluate the safety and absorption profile of a single oral dose of XXX (75mg) in migraine patients during an attack.

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of XXX in Patients with Alzheimer's Disease.

Open evaluation of the long-term efficacy, safety and tolerability of XXX in the acute treatment of migraine attacks.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Cardiovascular Safety of XXX in Patients Suffering From An Acute Migraine Episode.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Multicenter, Dose-Range-Finding Study to Assess the Efficacy Tolerability and Safety of XXX (Administered as a Single Dose of 0.5 mg, 2.5 mg. Or 5.0 mg) in the Acute Treatment of Migraine.

A Randomized, Double-Blind, Placebo-Controlled, Twelve-Month Safety and Efficacy Trial of 120, 240, and 360 mg tid of XXX) in Patients with Probable Alzheimer's Disease.

Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of a Fixed Dose XXX Tablet XXX Comparing a Loading Dose Phase and No Loading Dose Phase Versus Placebo in Patients with Probable Alzheimer's Disease.

Double-Blind, Placebo-Controlled Study of XXX and XXX in Geriatric Outpatients with Major Depression

A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Single Dose of XXX in the Treatment of Acute Migraine.

A Randomized, Triple-Blind, Placebo-Controlled, Parallel Groups,Outpatient Study to Examine the Safety, Tolerability, and Efficacy of XXX (XXX) 10 mg RPD and 5 mg RPD for the Acute Treatment of Migraine.

A Double-Blind, Randomized Trial of Two Dose Ranges of XXX and Placebo in the Prophylactic Treatment of Migraine.

An Open Extension Study of the Long Term Safety and Efficacy of XXX (25 ug BID or 50 ug BID) in Patients Suffering from Dementia of the Probable Alzheimer's Type.

Long-Term Treatment with XXX (XXX) for Patients with Probable Alzheimer's Disease.
A Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of XXX (XXX) in Patients with Probable Alzheimer's Disease.

Open-Label Extension of XXX Registration Phase Efficacy Trials Using XXX Transdermal Therapeutic System (TTS).

An Open-Label, Multicenter, Clinical Trial Evaluating the Safety and Efficacy of XXX (XXX) in Patients with Alzheimer's Disease.

A Double-Blind, Placebo-Controlled Study of XXX and XXX in Geriatric Outpatients with Major Depression.

A multicentre, double-blind, placebo-controlled, randomized, parallel group study to evaluate the safety and absorption profile of a single oral dose of XXX (75mg) in migraine patients during an attack.

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of XXX in Patients with Alzheimer's Disease.

Open evaluation of the long-term efficacy, safety and tolerability of XXX in the acute treatment of migraine attacks.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Cardiovascular Safety of XXX in Patients Suffering From An Acute Migraine Episode.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Multicenter, Dose-Range-Finding Study to Assess the Efficacy Tolerability and Safety of XXX (Administered as a Single Dose of 0.5 mg, 2.5 mg, Or 5.0 mg) in the Acute Treatment of Migraine.

A Randomized, Double-Blind, Placebo-Controlled, Twelve-Month Safety and Efficacy Trial of 120, 240, and 360 mg tid of XXX) in Patients with Probable Alzheimer's Disease.

A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of a Fixed Dose XXX Tablet XXX Comparing a Loading Dose Phase and No Loading Dose Phase Versus Placebo in Patients with Probable Alzheimer's Disease.

A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Single Dose of XXX in the Treatment of Acute Migraine.

A Randomized, Triple-Blind, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of XXX (XXX) 10 mg RPD and 5 mg RPD for the Acute Treatment of Migraine.
A Double-Blind, Randomized Trial of Two Dose Ranges of XXX and Placebo in the Prophylactic Treatment of Migraine.

An Open Extension Study of the Long Term Safety and Efficacy of XXX (25 ug BID or 50 ug BID) in Patients Suffering from Dementia of the Probable Alzheimer's Type.

An 8-Week Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX Therapy When Administered to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Using a Twice Daily Dosing Regimen.

Long-Term Treatment with XXX (XXX) for Patients with Probable Alzheimer's Disease.

A Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of XXX (XXX) in Patients with Probable Alzheimer's Disease.

The Long Term Safety and Efficacy of XXX in The Treatment of Alzheimer's Disease.

A 30-Week, Open-Label Evaluation of XXX in Patients with Dementia Associated with Cerebrovascular Disease

A Double-Blind, 12-Month Safety and Efficacy Extension Study of XXX (XXX) 120 mg tid, 240 mg tid, and 360 mg tid in Patients with Probable Alzheimer's Disease.

Long-term Safety and Efficacy of XXX In The Treatment of Alzheimer's Disease.

The Safety and Efficacy of XXX for the Prevention of Alzheimer's Disease in Patients at Risk.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate the Efficacy of Oral XXXXXX (2.5 MG) For The Treatment of Migraine in Subjects Who Do Not Respond To Oral XXX (50 MG).

XXXXX Versus XXXXX and Paroxetine in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms

A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety, Tolerability and Efficacy of XXXXXX 5 mg P.O. for the Acute Treatment of Migraine in Adolescents.

A Randomized, double-blind, Placebo-controlled, Four-Arm-Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of XXX in Patients with Alzheimer's Disease.
An Open-Label Extension Study to Evaluate the Long term Safety and Tolerability of XXXX in patients with mild to moderate Alzheimer's Disease.

A Double-blind, Randomized Trial of Two Dose Ranges of XXXX and Placebo in the Prophylactic Treatment of Migraine.

A Randomized, Double-Blind, 12-Month Safety and Efficacy Trial of XXX mg tid and 360 mg tid or Placebo Added to Treatment with Donepezil HCl 10 mg qd in Patients with Probable Alzheimer's Disease.

A Randomized, Double-Blind, Placebo-Controlled, 12-Month Safety and Efficacy Trial of XXX 240 mg tid and 360 mg tid in Patients with Probable Alzheimer's Disease.

A Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate XXX in Patients with Possible Alzheimer's Disease of Mild to Moderate Severity.

Bleeding Profile with Continuous-Combined Hormone Replacement Therapy: A Randomized, Double-blind, Multicenter, Comparative Trial of 1 mg XXX in Combination with 0.25 mg or 0.5 mg XXX and XXX

A Six-Week, Double-Blind, Placebo and XXX-Controlled Multi-Center Study to Evaluate The Safety and Efficacy of Oral XXX In Outpatients with Major Depressive Disorder

A Double Blind, Randomized, Multicenter, Parallel Design to Evaluate the Efficacy and Safety of Three Dose Ranges of XXX in Comparison with Placebo and Fluoxetine in Outpatients with Major Depressive Disorder.

The Safety and Efficacy of XXX for the Prevention of Alzheimer's Disease in Patients at Risk.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate XXX in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity.

A Double Blind, Randomized, Multicenter, Parallel Design to Evaluate the Efficacy and Safety of Three Dose Ranges of XXX in Comparison with Placebo and XXX in Outpatients with Major Depressive Disorder.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of XXX or XXX In Postmenopausal Women with Mild to Moderate Alzheimer’s Disease.

XXX Versus XXX and Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia.
A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of XXX Hydrochloride (XXX) In Subjects with Mild Cognitive Impairment.

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of XXX Hydrochloride (XXX) In Patients with Early Alzheimer’s Disease.

A Randomized, Double-Blind, Placebo-Controlled Multi-Country Study of Two Treatment Strategies for Patients with Mild to Moderate Alzheimer’s Disease who do not show Clinical Improvement after 12 to 24 Weeks of XXX Treatment.

A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of XXX in Patients with Mild to Moderate Probable Alzheimer’s Disease.

A Double-Blind, Placebo-Controlled, Parallel Assessment of the Safety and Efficacy of the XXX System in Subjects With Major Depression.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Dose Study to Evaluate the Safety and Efficacy of 50, 300, and 600mg/day Of XXX in Patients with Mild to Moderate Alzheimer’s Disease.

An Open-Label Study to Evaluate the Adhesiveness, Skin Irritation, and Safety of Different Sizes of XXXDS Variant XXX Patches in Patients with Mild to Moderately Severe Alzheimer’s Disease.

A Single Dose, Double-Blind, Safety and Efficacy Study XXX, XXX Hydrochloride and XXX in Subjects with Acute Migraine Attacks.

A Safety and Pharmacokinetic Study of XXX® and XXX® in Parkinson’s Disease (PD) Patients Compared To Healthy Volunteers Administered XXX® Alone

Sustained Efficacy Study of XXX In Patients With Panic Disorder With or Without Agoraphobia

An Open Label, Repeat Dose, Long-Term Safety Study of XXX in Subjects with Acute Migraine Attacks.

XXX, Placebo, and XXX Comparison in Patients With Major Depressive Disorder.

Randomized, double-blind, placebo-controlled multicenter trial to demonstrate the clinical efficacy and safety of two different doses of XXX special extract XXX in patients suffering from Dementia of the Alzheimer's Type according to DSM-IV and NINCDS/ADRDA criteria.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dosages of XXX® (XXX, Type A) Purified XXX Complex for the Prophylactic Treatment of Migraine Headaches.

Double-Blind Follow-up Interview Study of Subjects Who Participated in Protocol XXX. ("A Six-Week, Double-Blind, Placebo and XXX-Controlled Multi-Center Study to Evaluate The Safety and Efficacy of Oral XXX In Outpatients with Major Depressive Disorder. ")

Ninety Day Safety Study of XXX- in Male and Female Parkinson’s Patients on XXX + XXX